Evaluation of the Clinical Value of KL-6 and Tumor Markers in Primary Sjögren's Syndrome Complicated with Interstitial Lung Disease.

CA153 CEA KL-6 interstitial lung disease primary Sjögren’s syndrome

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
27 Jul 2023
Historique:
received: 24 11 2022
revised: 19 03 2023
accepted: 21 07 2023
medline: 12 8 2023
pubmed: 12 8 2023
entrez: 12 8 2023
Statut: epublish

Résumé

primary Sjögren's syndrome (pSS) is an autoimmune disease, of which the most common complication is interstitial lung disease (ILD). This study aimed to analyze the clinical value of Krebs von den Lungen-6 (KL-6), carcinoembryonic antigen (CEA), and carbohydrate antigen 153(CA153) in patients with pSS complicated with ILD (pSS-ILD), given that only few studies have evaluated this. This is a cross-sectional study. Serum KL-6 levels (U/mL) were measured using chemiluminescence immunoassay, and concentrations of serum tumor markers were determined using the immunofluorescence method in 64 cases of pSS-ILD (pSS-ILD group), 23 cases without ILD (non-ILD group), and 45 healthy controls. The correlation between KL-6 and tumor markers as well as lung function was analyzed, and the factors that were associated with pSS-ILD were screened. The serum KL-6 was more abnormally increased in patients with pSS-ILD, and the serum KL-6, CEA, carbohydrate antigen 125 (CA125), and CA153 levels were significantly higher in the pSS-ILD group than in the non-ILD and healthy control groups ( In conclusion, we evaluated the association between clinical values of KL-6, tumor markers, and pSS-ILD, and found that KL-6 and tumor markers such as CEA, CA153, and CA125 in patients with pSS-ILD were higher than in patients with non-ILD, and KL-6 was more abnormally increased and significantly associated with ILD development in patients with pSS.

Identifiants

pubmed: 37568332
pii: jcm12154926
doi: 10.3390/jcm12154926
pmc: PMC10419721
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : National Key R & D Program of China
ID : 2021YFC2500700

Références

Int J Gen Med. 2021 Jun 15;14:2553-2560
pubmed: 34163223
Clin Rheumatol. 2019 Aug;38(8):2181-2187
pubmed: 30888566
Curr Protoc Pharmacol. 2017 Mar 17;76:9.23.1-9.23.17
pubmed: 28306150
Arthritis Res Ther. 2019 Feb 14;21(1):58
pubmed: 30764869
J Med Virol. 2020 Oct;92(10):2216-2220
pubmed: 32470148
BMC Pulm Med. 2020 Jan 8;20(1):6
pubmed: 31915006
Eur Respir J. 2018 Sep 6;52(3):
pubmed: 30072507
Arthritis Res Ther. 2022 May 19;24(1):115
pubmed: 35590341
Ther Adv Chronic Dis. 2020 Jul 30;11:2040622320944802
pubmed: 32843956
Sichuan Da Xue Xue Bao Yi Xue Ban. 2018 Mar;49(2):195-199
pubmed: 29737059
Rheumatol Ther. 2021 Mar;8(1):517-527
pubmed: 33586127
Autoimmun Rev. 2020 Feb;19(2):102447
pubmed: 31843713
Sci Rep. 2022 Mar 29;12(1):5343
pubmed: 35351939
Int J Rheum Dis. 2019 Jan;22(1):108-115
pubmed: 30592376
Respirology. 2014 Jul;19(5):707-13
pubmed: 24903079
Clin Respir J. 2017 May;11(3):337-345
pubmed: 26077281
Clin Respir J. 2022 Mar;16(3):234-243
pubmed: 35081277
Front Immunol. 2020 Jul 14;11:1443
pubmed: 32760396
Sci Rep. 2022 Mar 22;12(1):4916
pubmed: 35318424
Chron Respir Dis. 2020 Jan-Dec;17:1479973120958428
pubmed: 32969271
Autoimmun Rev. 2017 Jan;16(1):48-54
pubmed: 27682894
J Inflamm Res. 2022 Apr 08;15:2255-2262
pubmed: 35422651
Respir Med. 2019 Nov;159:105811
pubmed: 31710871
Arch Rheumatol. 2017 Oct 16;33(2):190-197
pubmed: 30207560
Sarcoidosis Vasc Diffuse Lung Dis. 2015 Sep 14;32(3):228-36
pubmed: 26422568
Mod Rheumatol. 2019 Jul;29(4):625-632
pubmed: 30484723
Arthritis Rheumatol. 2019 Dec;71(12):2059-2067
pubmed: 31233287
Dis Markers. 2016;2016:4759040
pubmed: 27293304
Respirology. 1998 Sep;3(3):199-202
pubmed: 9767620
Front Immunol. 2021 Dec 09;12:745233
pubmed: 34956179
Arthritis Rheumatol. 2021 Apr;73(4):677-686
pubmed: 33118321
Clin Exp Rheumatol. 2020 Jul-Aug;38 Suppl 126(4):291-300
pubmed: 33095142
Clin Exp Rheumatol. 2016 Jul-Aug;34(4):587-91
pubmed: 27213221
Medicine (Baltimore). 2021 Sep 3;100(35):e26777
pubmed: 34477117
Anticancer Res. 2009 Oct;29(10):4239-42
pubmed: 19846980
Eur J Med Res. 2022 Oct 10;27(1):199
pubmed: 36217184

Auteurs

Fengqin Wei (F)

Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, Capital Medical University, Beijing 100029, China.
National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing 100029, China.
Department of Pulmonary and Critical Care Medicine, Qingdao Municipal Hospital, Qingdao 266011, China.

Xinran Zhang (X)

National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing 100029, China.
Department of Clinical Research and Data Management, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing 100029, China.

Shengnan Yang (S)

Department of Pulmonary and Critical Care Medicine, Tianjin Chest Hospital, Tianjin 300222, China.

Jing Geng (J)

Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, Capital Medical University, Beijing 100029, China.
National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing 100029, China.

Bingbing Xie (B)

Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, Capital Medical University, Beijing 100029, China.
National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing 100029, China.

Yanhong Ren (Y)

Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, Capital Medical University, Beijing 100029, China.
National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing 100029, China.

Huaping Dai (H)

Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, Capital Medical University, Beijing 100029, China.
National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing 100029, China.

Classifications MeSH